

ALTEA THERAPEUTICS REPORTS POSITIVE RESULTS FOR BASAL INSULIN TRANSDERMAL PATCH- DIABETES THERAPY

Drug Week, Sec. Editor's Choice, March 02, 2007

Altea Therapeutics announces positive clinical results from phase I human clinical studies for its basal insulin transdermal patch showing efficient, sustained and constant delivery of insulin at therapeutic levels.

These results were presented at the 11th Annual Drug Delivery Partnerships Conference held in Las Vegas, Nevada, In a glucose-clamp study in normal subjects, Altea Therapeutics achieved constant insulin delivery at therapeutic levels over a 12-hour patch application period.

The data show efficient delivery of the applied dose of insulin and demonstrate favorable pharmacodynamics of transdermal insulin delivery when compared to a subcutaneous injection of a long-acting insulin analog. Altea Therapeutics is developing both 12-hour and 24-hour transdermal patches based on its proprietary PassPort System to provide constant 'basal' levels of insulin for people with type 1 or type 2 diabetes.

"We are delighted to achieve such promising results," said Eric Tomlinson, president and CEO of Altea Therapeutics. "These findings are very important to our clinical development program as they confirm efficient and constant delivery of basal insulin from our PassPort Patch. These results give us confidence that basal insulin transdermal patches can be a cost effective alternative for people currently using insulin injections to manage their diabetes. A higher patient acceptance of a basal insulin transdermal patch over needle injections enables physicians to start subjects earlier on insulin in the management of type 1 and type 2 diabetes."

Market research conducted by Altea Therapeutics on its transdermal basal insulin product confirms significant market potential for a pain-free, convenient and cost-effective alternative to repeat insulin injections. Approximately 40 to 50 million people with type 2 diabetes and 10 million people with type 1 diabetes worldwide require insulin therapy. The worldwide market for all forms of insulin was over \$7 billion in 2005 and is estimated at over \$11 billion by 2011. The basal insulin is the fastest growing market and generated over \$2.6 billion in 2005.